Inhibition of hIAPP Amyloid-Fibril Formation and Apoptotic Cell Death by a Designed hIAPP Amyloid- Core-Containing Hexapeptide  by Tatarek-Nossol, Marianna et al.
Chemistry & Biology, Vol. 12, 797–809, July, 2005, ©2005 Elsevier Ltd All rights reserved. DOI 10.1016/j.chembiol.2005.05.010
Inhibition of hIAPP Amyloid-Fibril Formation and
Apoptotic Cell Death by a Designed hIAPP Amyloid-
Core-Containing Hexapeptide
Marianna Tatarek-Nossol,1,3 Li-Mei Yan,1,3
Anke Schmauder,1 Konstantinos Tenidis,1
Gunilla Westermark,2 and Aphrodite Kapurniotu1,*
1Laboratory of Bioorganic and Medicinal Chemistry
Institute of Biochemistry
University Hospital of the Rheinisch-Westfälische
Technische Hochschule Aachen
D-52074 Aachen
Germany
2Department of Biomedicine and Surgery
Cell Biology
Linköping University
SE-58185 Linköping
Sweden
Summary
The pathogenesis of type II diabetes is associated
with the aggregation of the 37-residue human islet
amyloid polypeptide (hIAPP) into cytotoxic  sheet
aggregates and fibrils. We have recently shown that
introduction of two N-methyl rests in the  sheet- and
amyloid-core-containing sequence hIAPP(22–27), or
NFGAIL converted this amyloidogenic and cytotoxic
sequence into nonamyloidogenic and noncytotoxic
NF(N-Me)GA(N-Me)IL. Here, we show that NF(N-Me)
GA(N-Me)IL is able to bind with high-affinity full-length
hIAPP and to inhibit its fibrillogenesis. NF(N-Me)GA
(N-Me)IL also inhibits hIAPP-mediated apoptotic 
cell death. By contrast, unmodified NFGAIL does not
inhibit hIAPP amyloidogenesis and cytotoxicity, sug-
gesting that N-methylation conferred on NFGAIL the
properties of NF(N-Me)GA(N-Me)IL. These results sup-
port the concept that rational N-methylation of hIAPP
amyloid-core sequences may be a valuable strategy
to design pancreatic-amyloid diagnostics and thera-
peutics for type II diabetes.
Introduction
Type II diabetes is a pancreatic β cell-degenerative dis-
ease that today affects about 200 million people world-
wide and leads, through progressively increasing pe-
ripheral insulin resistance and decline of β cell function,
to a severe deterioration of the physiological functions
that are under glycemic control and to a number of
micro- and macrovascular complications [1, 2]. A char-
acteristic pathophysiological feature of more than 95%
of the type II diabetics is the formation of amyloid de-
posits in the pancreas [1, 3].
Pancreatic-amyloid deposits in humans consist
mainly of β sheet fibrillar aggregates of the 37-residue
polypeptide human islet amyloid polypeptide (hIAPP)*Correspondence: akapurniotu@ukaachen.de
3 These authors contributed equally to this work.(Figure 1A) [4]. hIAPP is expressed in the β cells, and in
its soluble form, it is believed to play an important role
in glucose homeostasis, most likely as an insulin counter-
regulator [5, 6]. Insoluble hIAPP amyloid aggregates,
however, colocalize with degenerated β cells, and their
formation is linked to the progressive deterioration of β
cells and type II diabetes pathogenesis [1, 3, 7]. In addi-
tion, soluble oligo- and multimeric hIAPP amyloid ag-
gregates have been suggested to be cytotoxic [8–11].
Although both the self-assembly state and the morpho-
logical features of the cytotoxicity-mediating hIAPP
species are yet to be identified, substantial amount of
evidence suggests that these species may form within
the pathway of hIAPP amyloid fomation [8–12]. The lat-
ter one is a not yet fully understood, multistep nucle-
ation- and concentration-dependent process that pro-
ceeds via a conformational transition of mainly random
coil hIAPP into β sheet-containing amyloid aggregates
[11, 13, 14]. In addition, there is a clear species and
sequence specificity of the amyloidogenic potential of
the hIAPP sequence [8]. For example, the rat hIAPP se-
quence (rIAPP) differs in 6 out of 37 residues from the
human one and is not capable of forming amyloid fi-
brils.
To date, two classes of inhibitors of hIAPP amyloido-
genicity and/or cytotoxicity have been described. The
first one includes aromatic organic compounds such as
Congo red, rifampicin, and others that bind to amyloid
fibrils and/or suppress amyloid-fibril formation [15–19].
Some of the compounds have been reported also to
inhibit hIAPP cytotoxicity and to inhibit amyloidogeni-
city and/or cytotoxicity by other amyloid peptides [16,
18, 19]. The second class of inhibitors consists of short
synthetic peptides that have been derived from hIAPP
sequences that contain hIAPP self-recognition domains.
These inhibitors are short partial hIAPP sequences in a
nonmodified form, i.e., hIAPP(20–25) and hIAPP(24–29)
[20], whereas very recently, short hIAPP self-recogni-
tion sequences carrying α-aminoisobutyric acid (Aib)
have also been reported to inhibit hIAPP amyloid for-
mation [21]. However, although some of the above pep-
tides have been shown to be able to inhibit hIAPP amy-
loidogenesis, to date, only one of them, hIAPP(20–25),
has been reported to be capable of reducing both
hIAPP amyloid formation and cytotoxicity [20]. There-
fore, rationally designed compounds that may be able
to interfere with the amyloid-fibril formation pathway of
hIAPP and affect both hIAPP fibril formation and related
cytotoxicity are important tools for both understanding
the mechanism of hIAPP-amyloidogenesis-related cy-
totoxicity and developing novel molecular strategies for
the treatment of type II diabetes.
We have recently applied a chemical strategy to con-
vert short, amyloidogenic, and cytotoxic hIAPP se-
quences into highly soluble, nonamyloidogenic, and
noncytotoxic ones [22]. This has been achieved via the
introduction of conformational constraints in form of
N-methylation of two selected amide bonds within
short hIAPP sequences containing an hIAPP “amyloid-
core” region. The strategy of N-methylation of peptide
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798Figure 1. Primary Structures of Peptides
Used in This Study and Inhibition of hIAPP β
Sheet Formation and Fibrillogenesis by the
Designed Inhibitor as Studied by CD and EM
(A) Scheme showing the primary structure of
hIAPP, the designed N-methylated hexapep-
tide (in bold), and various control peptides.
The residues of the hIAPP amyloid-core re-
gion hIAPP(22–27) are shown in bold. The
one-letter code is used for the amino acids.
hIAPP contains an amide at the C terminus,
whereas the other sequences are peptide
acids.
(B–E) Interaction of NF(N-Me)GA(N-Me)IL with
hIAPP and its inhibitory effect on hIAPP aggre-
gation into β sheets and amyloid-fibril forma-
tion as assessed by CD (B and C) and EM (D
and E). (B) CD spectra of hIAPP alone (5 M)
at various time points of the incubation show
that the conformational transition into aggre-
gated β sheets and insolubilization are accom-
plished at about 7 days after the beginning of
the incubation. (C) CD spectrum of the mixture
of hIAPP (5 M) with NF(N-Me)GA(N-Me)IL (50
M) at time 0 min and a representative
spectrum for the time period 6–14 days are
shown. For comparison, the spectra of hIAPP
and of NF(N-Me)GA(N-Me)IL alone and also the mathematical addition of the hIAPP and NF(N-Me)GA(N-Me)IL spectra (at 0 min) are shown. (D)
Representative electron micrograph of the hIAPP solution of the CD experiment of (B) (hIAPP alone) after incubation for 7 days and appearance
of insoluble aggregates. (E) Representative electron micrograph of the solution of the CD experiment showed in (C) (hIAPP with NF[N-Me]GA
[N-Me]IL) after incubation for 14 days. Bars in the electron micrographs represent 100 nm.amide bonds has been a well-known protein-design ap- g
bproach to suppress the H-bonding ability of an NH
group and to restrict the conformation of the backbone m
f[23–26]. Also, recently, studies on the applicability of
N-methylated sequences of the Alzheimer’s peptide f
gβ-amyloid peptide (Aβ) for inhibition of Aβ amyloid for-
mation have been reported [27, 28]. According to our d
odesign approach, short hIAPP amyloid-core-containing
sequences that have been double N-methylated on the
one side of the β strand should be able to interact with R
their amyloid-forming precursor sequences and possi-
bly inhibit amyloid formation and cytotoxicity [22]. One T
iof the hIAPP amyloid-core sequences that we modified
was the hexapeptide hIAPP(22–27) or NFGAIL (Figure m
e1A). NFGAIL has been previously identified as a short
hIAPP “amyloid-core”-containing sequence that is able 3
sto self-associate into β sheets and cytotoxic amyloid
fibrils [29–31]. Based on an NMR-derived model of pan- w
ncreatic amyloid, N-methylations were introduced at
Gly24 and Ile26, and we devised NF(N-Me)GA(N-Me)IL [
i(Figure 1A) [22, 32]. In fact, NF(N-Me)GA(N-Me)IL was
found to be highly soluble, unable to aggregate into β s
csheets and cytotoxic amyloid, and inhibited amyloid
formation by its precursor hexapeptide NFGAIL [22]. e
tBased on these results and the hypothesis that NFGAIL
might represent a crucial self-recognition and amyloid- a
pcore sequence of full-length hIAPP, NF(N-Me)GA
(N-Me)IL appeared to be a promising candidate for inhi- t
abition of amyloid-fibril formation and cytotoxicity of
hIAPP [29–32]. a
3Here, we present biophysical and biochemical studies
on the interaction of NF(N-Me)GA(N-Me)IL with hIAPP a
mand its effect on hIAPP amyloid-fibril formation and cy-
totoxicity. The interaction of NF(N-Me)GA(N-Me)IL with N
ehIAPP and its effects on hIAPP conformation and ag-regation into β sheets and amyloid fibrils were studied
y far-UV circular dichroism spectroscopy (CD), electron
icroscopy (EM), fluorescence spectroscopy, the thio-
lavin T (ThT) binding assay, Congo red staining, and
luorescence microscopy. Its effects on hIAPP-aggre-
ate-mediated β cell death were studied by a formazan-
ye reduction cell viability assay and by assessment
f apoptosis.
esults
he interaction of NF(N-Me)GA(N-Me)IL with hIAPP and
ts interference with the β sheet and amyloid-fibril for-
ation process were first studied by a previously
stablished far-UV CD/EM experimental system [13,
3]. For the CD experiments, we used a 5 M hIAPP
olution (10 mM phosphate buffer [pH 7.4], 1% HFIP),
hich we have previously found to correspond to a ki-
etically soluble but supersaturated hIAPP solution
34]. The presence of small amounts (1%–4%) of HFIP
n hIAPP solutions has been found by us and others to
ynchronize and/or enhance hIAPP fibrillogenesis pro-
esses [12–14]. Of note, to ensure that the observed
ffects on hIAPP conformation were due to hIAPP-pep-
ide interaction, all solutions tested, including hIAPP
lone, the mixtures of hIAPP with the peptides, and the
eptides alone, contained the same final HFIP concen-
ration of 1%. hIAPP alone was initially soluble and in
predominantely unordered state and aggregated after
lag time of 7 days into β sheets (Figure 1B) [13, 35,
6]. At this time point, insoluble aggregates appeared,
nd EM after centrifugation showed that they consisted
ainly of amyloid fibrils (Figure 1D). In the presence of
F(N-Me)GA(N-Me)IL (at a 10-fold molar excess), how-
ver, the solution was clear, and no aggregation into β
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799sheets was observed for up to 14 days (Figure 1C). No
changes were observed in the UV spectrum during the
14 days, indicating that hIAPP was in a soluble state.
EM examination at various time points indicated the
absence of amyloid fibrils or other ordered aggregates
(Figure 1E).
The spectrum of the hIAPP/NF(N-Me)GA(N-Me)IL
mixture (1:10 ratio) at time 0 after the begin of incuba-
tion strongly differed from the sum of the spectra of
each component alone (at time 0), suggesting that NF
(N-Me)GA(N-Me)IL interacted with hIAPP [22]. The
spectrum of the mixture of hIAPP with NF(N-Me)GA
(N-Me)IL had a strong minimum at 225–228 nm, a weak
minimum at 202–205 nm, and a weak maximum at 210
nm (Figure 1C). Notably, this spectrum showed signifi-
cant fluctuations during the study. Therefore, the [θ]225–228
value (turn/β sheet) became less while the [θ]202–205
value (random coil) increased by a similar amount and
vice versa (Figure 1C). CD spectra of NF(N-Me)GA(N-
Me)IL alone (50 M) showed no time-dependent con-
formational changes, indicating that the fluctuations
might be due to the interaction of NF(N-Me)GA(N-Me)IL
with hIAPP. Of note, even when hIAPP was mixed with
NF(N-Me)GA(N-Me)IL at an 1:1 or 1:0.1 ratio, in which
low or no contribution of the CD spectrum of NF(N-
Me)GA(N-Me)IL to the CD spectrum of the mixture was
observed, the shapes of the spectra were very similar
to the spectrum of the 1:10 mixture (data not shown).
However, NF(N-Me)GA(N-Me)IL was not able to signifi-
cantly inhibit β sheet formation and to delay hIAPP in-
solubilization at hIAPP/NF(N-Me)GA(N-Me)IL molar ra-
tios of 1:1 and 1:0.1.
We next examined the effect of NFGAIL on hIAPP
aggregation into β sheets and amyloid fibrils by CD and
EM [20, 29]. Although NFGAIL is an amyloidogenic pep-
tide per se, it has a high kinetic solubility (in the milimo-
lar range) as compared to IAPP (in the nanomolar
range) [29]. Therefore, it was expected that NFGAIL
would remain soluble during the time course of the CD
study. In Figure 2A, CD spectra of an hIAPP solution (5
M) before and after addition of NFGAIL (50 M) for up
to 14 days are shown. At 14 days, insoluble amyloid
fibrils precipitated out of solution (Figure 2B). RP-HPLC
analysis of the precipitate after resolubilization in
DMSO showed that the aggregates consisted exclu-
sively of hIAPP (data not shown). The conformation and
solubility of NFGAIL (50 M) were also followed over
time, and no changes or precipitation were observed
for 14 days. Although the CD studies indicated that
NFGAIL could not inhibit hIAPP amyloidogenesis, the
fluctuations of the spectrum of the mixture and the
marked difference between the spectrum of the mixture
at time 0 from the sum of the spectra of each peptide
(at time 0) indicated that NFGAIL interacted with hIAPP
[20]. The effect of the rat IAPP (rIAPP) sequence
rIAPP(22–27) or NLGPVL on hIAPP was next examined
by CD/EM (Figures 2C and 2D). This sequence, al-
though partially homologous to hIAPP(22–27) or NFGAIL,
has no amyloidogenic properties [29, 37, 38]. When
hIAPP was incubated with NLGPVL (50 M), insoluble
hIAPP amyloid fibrils—as confirmed by EM and RP-
HPLC analysis of the resolubilized aggregates—precip-
itated at 5 days (Figures 2C and 2D). We also tested
the effect of the scrambled N-methylated sequence(N-Me)IAF(N-Me)GNL (50 M) on the conformational
transition of hIAPP (5 M) into β sheets and amyloid
formation by CD and EM. No inhibition of the aggrega-
tion into β sheets and amyloid formation was observed
(data not shown).
The thioflavin-T assay was next used to obtain a
quantitative estimation of the effect of NF(N-Me)GA
(N-Me)IL and the control peptides on hIAPP fibrillogen-
esis (Figures 3A and 3B). Amyloid fibrils of polypeptides
and proteins, including hIAPP, bind the dye ThT, and
the increase in ThT fluorescence emission is broadly
used as a specific and quantitative assay for fibril for-
mation [39, 40]. In contrast to the conditions used for
the CD studies, the ThT assay was performed in the
absence of HFIP (6.25 M hIAPP in aqueous Tris buffer
[pH 7.4]) because according to studies by us and oth-
ers, HFIP, even at 1%–2%, results in a strong accelera-
tion of hIAPP fibrillization [14, 41]. However, a ThT sys-
tem describing the complete pathway, including both
pre- and postnucleation, is required to investigate the
effect of potential inhibitors on fibrillogenesis. The pro-
file of hIAPP-fibril formation obtained was consistent
with nucleation-dependent fibrillogenesis and showed
a lag time of about 50 hr (Figure 3A). Thereafter, a steep
increase in ThT fluorescence was observed that corre-
lated with an increase in the amount of amyloid fibrils,
which was confirmed by EM. Fluorescence increase
was followed by a plateau, which indicated the end of
the fibrillization process. In the presence of NF(N-Me)
GA(N-Me)IL (10-fold excess), however, the lag time was
longer, and the ThT fluorescence was markedly less
than in the hIAPP solution after 14 days (Figure 3A).
NF(N-Me)GA(N-Me)IL also inhibited hIAPP fibrillogen-
esis significantly when it was applied at a 10-fold lower
concentration (625 nM) than hIAPP (Figure 3A). Inhibi-
tion was stronger when NF(N-Me)GA(N-Me)IL was ap-
plied at a 10-fold excess than at a 10-fold lower con-
centration than hIAPP (Figure 3A). The kinetic profiles
of ThT assays suggested that NF(N-Me)GA(N-Me)IL
caused both a significant elongation of the lag time and
a reduction of the amount of fibrils formed. However,
NF(N-Me)GA(N-Me)IL (up to a 10-fold excess) did not
completely stop the hIAPP amyloidogenesis process.
In other ThT experimental sets, we addressed the ques-
tion of whether NF(N-Me)GA(N-Me)IL was able to stop
already seeded hIAPP amyloid-fibril formation pro-
cesses. These experiments were performed in buffers
containing 1% or 2% HFIP and indicated that NF(N-
Me)GA(N-Me)IL (10-fold excess) delayed but did not
stop fibrillogenesis (data not shown). Strong effects of
the applied buffers and HFIP contents on the inhibitory
effect on fibrillogenesis were also observed in these
studies. No inhibition of hIAPP fibrillogenesis was ob-
served by the control peptides NFGAIL, (N-Me)IAF(N-
Me)GNL, and the N-methylated peptide AA(N-Me)
GA(N-Me)VV that was derived from human prion protein
PrP(117–122) and is homologous to NF(N-Me)GA(N-
Me)IL (Figure 3B).
A detailed EM study of solutions of ThT assays was
performed next (Figures 4A–4F). In Figures 4A–4D, spe-
cies present in the ThT solution of hIAPP (Figure 3A)
and the mixtures of hIAPP/NF(N-Me)GA(N-Me)IL (1:10)
at 14 days (endpoint of fibrillization) are shown. The
hIAPP solutions consisted mainly of mature fibrils (Fig-
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800Figure 2. Interactions of hIAPP(22–27) or NFGAIL and rIAPP(22–27) or NLGPVL with hIAPP and Effect on hIAPP Amyloid-Fibril Formation as
Assessed by CD and EM
(A) CD spectra of the mixture of hIAPP (5 M) with NFGAIL (50 M) at time 0 min after the begin of the incubation and at 14 days are shown.
At this time point, insoluble hIAPP aggregates appeared. For comparison, the spectrum of hIAPP alone (at 0 min), of NFGAIL alone, and of
the mathematical addition of the CD spectra of hIAPP alone (at 0 min) and of NFGAIL alone (at 0 min) are also shown. In the inset, representa-
tive spectra of the mixture recorded between 0 and 10 min after the begin of the incubation are shown.
(B) Representative electron micrograph of the hIAPP with NFGAIL solution of the CD experiment of (A) after incubation for 14 days and
peptide insolubilization. The bar represents 100 nm.
(C) CD spectra of the mixture of hIAPP (5 M) with rIAPP(22–27) (NLGPVL) (50 M) at the time point 0 min and 5 days later are shown. At this
time point, insoluble hIAPP aggregates appeared. The spectrum of hIAPP alone (at 0 min), of NLGPVL alone (at 0 min), and of the mathematical
addition of the hIAPP and NLGPVL spectra (at 0 min) are shown.
(D) Representative electron micrograph of the hIAPP with NLGPVL mixture of the CD experiment of (A) after incubation for 5 days and peptide
insolubilization. The bar represents 100 nm.ure 4A). By contrast, the hIAPP/NF(N-Me)GA(N-Me)IL o
1(1:10) mixture (Figure 3A) consisted mainly of amor-
phous aggregates, ordered spherical species, short a
mcurly protofibril-like species, and mature fibrils (Figures
4B–4D). Ordered spherical and protofibril-like species
twere also main species in prenucleated mixtures of
hIAPP/NF(N-Me)GA(N-Me)IL (1:10) (i.e., incubations in a
bTris buffer containing 1% HFIP) (Figures 4E and 4F).
Figure 4E shows that short curly protofibrils and spheri- t
rcal aggregates were the main species present at 8 hr
after the begin of incubation, whereas Figure 4F shows d
ithat at 24 hr, mainly spherical species and mature fibrils
were present. A solution of hIAPP alone under these m
lconditions and at 24 hr consisted mainly of mature fi-
brils. These results indicated that the presence of NF t
[(N-Me)GA(N-Me)IL might have resulted in stabilizationf pre- and/or protofibrillar hIAPP species. Of note, the
4-day-old ThT-assay mixtures of hIAPP with NFGAIL
nd (N-Me)IAF(N-Me)GNL (also at 1:10) contained
ainly mature hIAPP fibrils.
We next tested if NF(N-Me)GA(N-Me)IL could affect
he cytotoxic effect of hIAPP aggregates on the pancre-
tic insulinoma cell line RIN5fm by using two-cell via-
ility assays. The first assay was the 3-[4,5-dimethyl-
hiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)
eduction assay that gives information about cellular re-
ox ability (Figure 5A). The latter one is a specific, early
ndicator of cell viability [42–44]. Because amyloid-
ediated cytotoxicity is associated with reduced cellu-
ar redox potential, this assay has found broad applica-
ion for studying the toxicity of amyloidogenic peptides
7, 15, 22, 29, 42–45]. Serial dilutions of a solution of
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801Figure 3. Effects of NF(N-Me)GA(N-Me)IL
and Various Control Peptide Sequences on
hIAPP Fibrillogenesis as Assessed by the
ThT Binding Assay
(A) ThT fluorescence versus time of hIAPP
(6.25 M) solutions or solutions of hIAPP
(6.25 M) with NF(N-Me)GA(N-Me)IL (62.5
M and 625 nM).
(B) ThT fluorescence versus time of hIAPP
(6.25 M) solutions or solutions of hIAPP
(6.25 M) with the control peptides NFGAIL,
AA(N-Me)GA(N-Me)VV, and (N-Me)IAF(N-Me)
GNL (625 nM). Similar results to the above
were obtained when the control peptides
were applied at 10-fold excess (62.5 M) as
compared to hIAPP. Data are the mean ±
SEM of three to six independent experi-
ments.seedless hIAPP (5 M) with or without NF(N-Me)GA(N-
Me)IL (at 50 M or 500 nM) were applied for 20 hr onto
the cells. After addition of MTT, cellular MTT reduction
was assessed [29]. The hIAPP/NF(N-Me)GA(N-Me)IL
mixtures both at a 1:10 and a 1:0.1 molar ratio were
significantly less cytotoxic than hIAPP alone, suggest-
ing that NF(N-Me)GA(N-Me)IL is an effective inhibitor of strongly depended on the aggregation and nucleation
Figure 4. Inhibition of hIAPP Fibrillogenesis by NF(N-Me)GA(N-Me)IL as Assessed by EM
(A) A representative electron micrographs of an hIAPP-alone incubation (6.25 M in Tris buffer [pH 7.4]) (incubation from Figure 3A) at 14
days that consisted mainly of mature fibrils.
(B–D) Representative electron micrographs of an hIAPP/NF(N-Me)GA(N-Me)IL (1:10) (6.25 M hIAPP in Tris buffer [pH 7.4]) mixture at 14 days
(incubation from Figure 3A) that consisted of amorphous aggregates (B), ordered spherical species (B), protofibril-like species (C), and mature
fibrils (D) are shown.
(E and F) Representative electron micrographs of an hIAPP/NF(N-Me)GA(N-Me)IL incubation (1:10) (6.25 M hIAPP, in Tris buffer [pH 7.4] with
1% HFIP) at 8 hr (E) and 24 hr (F). At 8 hr, the solution consisted mainly of short protofibril-like species and ordered spherical aggregates (E).
At 24 hr, mature fibrils and round spherical aggregates were the main species present (F).hIAPP toxicity (Figure 5A). Parts of the solutions that
were added to the cells were also examined by EM.
Amorphous aggregates and spherical hIAPP species
were present, whereas no mature amyloid fibrils were
detected (data not shown). It should be noted that the
effect of NF(N-Me)GA(N-Me)IL on hIAPP cytotoxicity
Chemistry & Biology
802Figure 5. Effects of NF(N-Me)GA(N-Me)IL
and Various Control Peptide Sequences on
hIAPP Cytotoxicity towards RIN 5fm Cells as
Assessed by the MTT Reduction Assay and
an Apoptosis Assay
(A and B) Cell viability in the presence of var-
ious concentrations of hIAPP alone versus
mixtures of hIAPP with NF(N-Me)GA(N-Me)IL
(1:10 and 1:0.1) (A) or the control peptide
sequences NFGAIL (1:10) and (N-Me)IAF
(N-Me)GNL (1:10 and 1:0.1) as indicated. Cell
viability was assessed after 20 hr incubation
of the above solutions with the cells via the
MTT reduction assay. Data are percentages
of control values and are the mean ± SEM of
at least four independent experiments with
each experiment performed in multiple repli-
cates (n = 4) except for the data of the
NFGAIL/hIAPP mixture, which are from one
representative experiment performed in trip-
licate.
(C) Apoptotic effect of hIAPP alone (500 nM)
versus a mixture of hIAPP (500 nM) with
NF(N-Me)GA(N-Me)IL (50 nM) on RIN 5fm
cells. Apoptosis was assessed after 20 hr in-
cubation of the above solutions with the
cells by ELISA quantification of cytosolic histone-associated nucleosomes. The data shown are from three independent experiments with
each experiment performed in multiple replicates (n = 4). The inhibitory effect of NF(N-Me)GA(N-Me)IL on hIAPP cytotoxicity was statistically
significant (p < 0.01 by ANOVA) (indicated by double asterisks). The difference between the effect of vehicle alone versus hIAPP was also
statistically significant (p < 0.001).state of hIAPP at the begin of incubation, and no signifi- i
ecant inhibitory effects were found in prenucleated solu-
tions. No inhibition of cytotoxicity was found in hIAPP w
bmixtures with AA(N-Me)GA(N-Me)VV, NFGAIL, and
(N-Me)IAF(N-Me)GNL (Figure 5B). t
oIt has been shown that β cell death caused by hIAPP
aggregates is mainly due to apoptosis [7, 8, 15, 46, 47]. 4
hWe therefore studied the effect of NF(N-Me)GA(N-Me)IL
on hIAPP-mediated apoptosis of RIN5fm cells (Figure o
t5C). We studied the effect of NF(N-Me)GA(N-Me)IL at a
molar ratio of hIAPP/NF(N-Me)GA(N-Me)IL of 1:0.1 be- c
icause according to the MTT assay, this ratio was suffi-
cient for a marked inhibition of hIAPP cytotoxicity. o
NQuantification of apoptosis was performed via quanti-
fication of cytoplasmatic histone-associated nucleo- o
esomes that are early indicators of apoptotic cell death
[48, 49]. hIAPP (500 nM) with or without NF(N-Me)GA F
r(N-Me)IL (50 nM) was incubated for 20 hr with the cells
and after cell lysis, histone-associated nucleosomes n
cwere quantified by an ELISA [47, 49]. As shown in Fig-
ure 5C, NF(N-Me)GA(N-Me)IL markedly inhibited hIAPP- (
Faggregate-mediated apoptotic cell death.
Fluorescence spectroscopy was applied by using 1
Gsynthetic, Nα-terminal-fluorescein-labeled hIAPP (Fluos-
hIAPP) to further characterize the interaction of NF s
I(N-Me)GA(N-Me)IL with hIAPP. In preliminary studies,
we found that Nα-terminal labeling of hIAPP with fluo-
arescein did not significantly affect the amyloidogenic
properties of hIAPP (L.-M.Y., M.T.-N., A. Velkova, A. Ka- h
mzantzis, and A.K., unpublished data). We also titrated
Fluos-hIAPP (1 nM) with hIAPP (10 pM–1 M) and de- w
atermined an apparent Kd of 10 nM for the Fluos-hIAPP-
hIAPP complex (L.-M.Y., M.T.-N., A. Velkova, A. Kazan- t
stzis, and A.K., unpublished data). To date, there have
been no reports about the affinity of the hIAPP-hIAPP snteraction. Biophysical studies have suggested, how-
ver, that it might be in the nanomolar range, which
ould be in good agreement with the value determined
y our fluorescence assay [8, 13, 14]. A directly propor-
ional concentration dependence was found for the flu-
rescence signal of Fluos-hIAPP alone between 1 and
nM. The above data suggested that 1 nM Fluos-
IAPP was either monomeric or at a stable monomeric/
ligomeric state at this low concentration range. Addi-
ion of NF(N-Me)GA(N-Me)IL at a 1000-fold molar ex-
ess (1 M) to the Fluos-hIAPP solution (1 nM) resulted
n a 100% enhancement of the fluorescence intensity
f Fluos-hIAPP (Figure 6A). This result suggested that
F(N-Me)GA(N-Me)IL binds monomeric and/or soluble
ligomeric hIAPP, and binding results in a change in the
nvironment of the fluorescein label. Titration of 1 nM
luos-hIAPP with NF(N-Me)GA(N-Me)IL (10 pM–10 M)
esulted in a sigmoidal curve and an apparent Kd of 129
M (± 59) (mean ± SEM of three independent binding
urves) for the hIAPP-NF(N-Me)GA(N-Me)IL complex
Figure 6B). Of note, no changes in fluorescence of
luos-hIAPP were found when it was mixed with a
000-fold molar excess of NFGAIL, (N-Me)IAF(N-Me)
NL, and AA(N-Me)GA(N-Me)VV, suggesting a high
pecificity of the observed hIAPP-NF(N-Me)GA(N-Me)
L interaction.
We next asked if NF(N-Me)GA(N-Me)IL would also be
ble to bind and, thus, stain in vivo-formed, insoluble
uman pancreatic-amyloid deposits. A solution of N-ter-
inal-fluorescein-labeled NF(N-Me)GA(N-Me)IL peptide
as applied to a human pancreatic tissue section with
n amyloid-containing islet. A consecutive tissue sec-
ion was stained with Congo red, which is an amyloid-
pecific dye [1, 50, 51]. Fluorescence microscopy
howed that, in fact, the fluorescently labeled peptide
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803Figure 6. Interaction of NF(N-Me)GA(N-Me)IL
with hIAPP as Studied by Fluorescence
Spectroscopy
(A) Fluorescence spectra of Fluos-hIAPP (1
nM) alone and after addition of NF(N-Me)
GA(N-Me)IL at various concentrations as in-
dicated.
(B) Binding curve (dashed lines) obtained
upon titration of Fluos-hIAPP (1 nM) with
NF(N-Me)GA(N-Me)IL. The affinity of the in-
teraction was estimated to be 129 nM. Data
shown are the mean ± SEM from three inde-
pendent binding curves (the fluorescence of
Fluos-hIAPP alone was subtracted).(Figure 7A, green fluorescence) binds in vivo-formed
amyloid deposits (Figure 7B, red fluorescence). The flu-
orescently labeled peptide did not bind to nonamyloid-
containing pancreatic tissue (Figures 7A and 7B). Other
synthetic hIAPP fragments, including hIAPP(1–13) or
NFGAIL, did not bind (hIAPP[1–13]) or bound nonspe-
cifically to pancreatic tissue (NFGAIL) (not shown). In
addition, no binding of fluorescently labeled NF(N-Me)
GA(N-Me)IL on secondary amyloidosis (AA)-derived
amyloid deposits of canine glomeruli was found (Fig-
ures 7C and 7D). These latter amyloid deposits derive
from serum amyloid A (SAA). Although more studies will
be necessary to demonstrate the specificity of the
staining of human pancreatic amyloid by fluorescently
labeled NF(N-Me)GA(N-Me)IL as compared to other
types of amyloid deposits, this latter result offers a first
indication that this might be the case.
Discussion
Based on a structure-based, selective N-methylation-
design approach, we have recently converted short,
amyloidogenic hIAPP self-recognition sequences into
soluble, nonamyloidogenic and noncytotoxic ones [22].
Based on the hypothesis that these sequences may mation that hIAPP adopted after interaction with NF
Figure 7. Interaction of Fluorescein-Labeled
NF(N-Me)GA(N-Me)IL with IAPP or AA Amy-
loid-Containing Tissues as Studied by Fluo-
rescence Microscopy
(A and B) Fluorescence microscopy of con-
secutive human pancreatic tissues contain-
ing amyloid deposits after staining with fluo-
rescently labeled NF(N-Me)GA(N-Me)IL (green)
(A) and Congo red (red) (B) (magnification
200×).
(C and D) Fluorescence microscopy of con-
secutive canine renal tissues with AA amy-
loid after staining with fluorescently labeled
NF(N-Me)GA(N-Me)IL (C) and Congo red (D)
(magnification 40×).contain an important hIAPP self-recognition element,
they were also expected to be able to interact with
hIAPP and interfere with its amyloid-forming pathway
[8, 52, 53]. One of the designed sequences is NF(N-Me)
GA(N-Me)IL that has been derived via rational N-meth-
ylation of the hIAPP amyloid-core hexapeptide hIAPP
(22–27) or NFGAIL [29–31, 54]. Here, we studied the
ability of NF(N-Me)GA(N-Me)IL to interact with hIAPP,
both in its soluble and in its pancreatic-amyloid form,
to interfere with the fibrillogenesis process of hIAPP
and to inhibit its amyloid-forming potential and related
toxicity toward β cells.
CD studies and EM suggested that NF(N-Me)GA
(N-Me)IL was in fact able to interact with hIAPP and to
inhibit its transition into aggregated β sheets and insol-
uble amyloid fibrils when applied at a 10-fold molar ex-
cess [8, 11, 13, 36]. The CD studies also indicated that
NF(N-Me)GA(N-Me)IL was able to interact with hIAPP
when it was also at a 10-fold-lower concentration than
hIAPP, whereas no inhibition of hIAPP fibrillogenesis
was observed under these conditions. Because CD re-
fers to overall conformation and because both peptides
may change their conformation upon interaction, it was
not possible to determine by this method the confor-
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804(N-Me)GA(N-Me)IL. However, the very low kinetic solu- o
Tbility of hIAPP (low micromolar to nanomolar range)
precluded the use of other biophysical methods, in- u
ucluding NMR or FT-IR. The CD spectra of the various
hIAPP/NF(N-Me)GA(N-Me)IL mixtures were characterized o
tby a reduced magnitude, in particular in the random
coil area, as compared to the spectrum of hIAPP alone, s
twhereas their shape was clearly indicative of the pres-
ence of significant amounts of ordered structure, i.e., β [
turn- and/or β strand-containing conformeric states
[22, 25–27, 35, 55, 56]. The observed conformational s
fordering in the hIAPP/NF(N-Me)GA(N-Me)IL mixtures
might reflect formation of ordered hIAPP-NF(N-Me)GA p
b(N-Me)IL complexes and/or an NF(N-Me)GA(N-Me)IL-
induced stabilization of soluble hIAPP oligomers [14, s
h41]. According to the design strategy, interaction of
NF(N-Me)GA(N-Me)IL with soluble hIAPP species might t
Ihave resulted in formation of ordered heterodimers and/
or heteromultimers [22]. In fact, detailed EM studies sug- t
pgested that ordered oligomeric assemblies including
prefibrillar spherical species and protofibril-like spe- a
acies formed.
The ThT/EM studies showed that NF(N-Me)GA(N-Me) b
fIL, at a 10-fold molar excess, was able to markedly de-
lay hIAPP fibrillogenesis and to strongly reduce the r
(amount of mature fibrils. Both findings were in good
agreement with the results of the CD studies. The ThT
Iassay also showed that NF(N-Me)GA(N-Me)IL was able,
even at a 10-fold-less concentration than hIAPP, to in- s
ohibit fibrillogenesis, albeit less effectively than at a 10-
fold-higher concentration. However, the results of the i
pThT/EM assays also showed that NF(N-Me)GA(N-Me)IL
was not able to completely block hIAPP fibrillogenesis. i
cAt first sight, these latter results appear to be contra-
dictory to the results of the CD/EM studies, which indi- A
bcated an absence of fibrillar or other ordered aggre-
gates in the hIAPP/NF(N-Me)GA(N-Me)IL (1:10) mixtures. a
aPotential reasons for the lack of detection of soluble
protofibrillar species include their possible adherence a
ton the windows of the CD cuvette and the possibility
that the examined EM samples did not contain all ag- b
sgregate species. This could be due to the fact that the
CD solutions have not been agitated before removing l
ssamples for EM because the smallest disturbance of
such supersaturated solutions may result in aggrega- F
mtion [34]. On the other hand, it is also likely that no solu-
ble ordered species or protofibrils were formed in the t
cCD solutions, contrary to what was observed in the ThT
solutions, because of the different experimental condi- s
dtions used in the two assays: the CD/EM assay was
performed in aqueous phosphate buffer containing 1% t
tHFIP with 5 M hIAPP, whereas for the ThT/EM assay,
a non-HFIP-containing Tris buffer system with 6.25 M N
VhIAPP was applied. The 1% HFIP conditions were well
suited for obtaining a kinetically stable but supersatu- s
trated hIAPP solution in the CD cuvette. However, when
we applied exactly the same experimental conditions t
has the ones used for the CD experiments to perform
incubations in eppendorf tubes and examined the in- b
rcubations with the ThT assay conditions, strongly pre-
nucleated systems with no lag times were obtained. t
wThese results were not unexpected as it is well known
how strongly small differences between experimental d
fsystems may affect the kinetics and thermodynamicsf protein oligomerization and fibrillogenesis [34, 57].
he above observations point out the limitations of the
se of a CD assay alone or in combination with EM and
nderline the importance of the use of a combination
f different assay systems and experimental conditions
o quantify the inhibitory potentials of compounds de-
igned to intervene with multistep processes such as
he protein and polypeptide fibrillization processes
13, 57].
Taken together, the CD, EM, and ThT assay results
uggested that NF(N-Me)GA(N-Me)IL strongly inter-
ered with the β sheet formation and fibrillogenesis
athway of hIAPP and inhibited formation of mature fi-
rils. In addition, these results indicated that the ob-
erved inhibitory effect of NF(N-Me)GA(N-Me)IL on
IAPP fibrillogenesis might most likely be due to its in-
eraction with monomeric or oligomeric IAPP species.
nteraction appears to cause a delay of nucleus forma-
ion and, thus, of the beginning of the fibrillogenesis
rocess, a stabilization of pre- or protofibrillar species,
nd a reduction of the amount of mature fibrillar IAPP
ggregates. Of note, no inhibitory effects on hIAPP fi-
rillogenesis with CD, EM, and ThT assays were found
or a number of control hexapeptides including NFGAIL,
IAPP(22–27), AA(N-Me)GA(N-Me)VV, and (N-Me)IAF
N-Me)GNL.
Direct evidence for the ability of NF(N-Me)GA(N-Me)
L to bind soluble monomeric and/or oligomeric hIAPP
pecies was obtained by fluorescence titration studies
f Fluos-hIAPP with NF(N-Me)GA(N-Me)IL. The changes
n fluorescence of fluorescently labeled proteins or
olypeptides are highly sensitive indicators of changes
n their environment such as changes that might be
aused by ligand binding or self-association [58–60].
n important advantage in applying fluorescence-
ased methods for the assessment of ligand binding to
polypeptide with high aggregation propensity, such
s hIAPP, is their high sensitivity [58]. The latter one
llows for very low concentrations of proteins/polypep-
ides, i.e., concentrations where the polypeptide might
e in a nonaggregated state, to be used. In fact, our
tudies indicated that Fluos-hIAPP at 1 nM was most
ikely at a stable monomeric and/or early oligomeric
tate (or states). Binding of NF(N-Me)GA(N-Me)IL to
luos-hIAPP caused a strong change in the environ-
ent of the N-terminal-fluorescein label, suggesting
hat binding is most likely associated with a strong
hange of conformation and/or assembly state (or
tates) of monomeric or oligomeric hIAPP. An apparent
issociation constant of 129 nM was derived from
he binding isotherm and suggested a high affinity for
he hIAPP-NF(N-Me)GA(N-Me)IL interaction. Importantly,
FGAIL, (N-Me)IAF(N-Me)GNL, and AA(N-Me)GA(N-Me)
V did not cause any changes in the fluorescence emis-
ion of Fluos-hIAPP, even at 1000-fold-higher concen-
rations than Fluos-hIAPP. These latter results indicated
hat these peptides either might have not bound Fluos-
IAPP species present at 1 nM or that they might have
ound, but binding did not induce changes in the envi-
oment of the N-terminal-fluorescein label. Regarding
he NFGAIL-hIAPP interaction, both interpretations
ould not be contradictory to the CD results, which in-
icated that NFGAIL interacted with hIAPP. One reason
or this is that the CD studies were performed at a
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8055000-fold-higher hIAPP concentration than the fluores-
cence measurements. Moreover, these findings sug-
gested that NFGAIL might bind hIAPP either in a dif-
ferent mode or much weaker than NF(N-Me)GA(N-Me)
IL, which might account for the observed inability of
NFGAIL to inhibit hIAPP fibrillogenesis and cytotoxicity.
Ten years ago, insoluble mature amyloid fibrils were
suggested to cause the cytotoxic effect of hIAPP [7].
However, in the past few years, evidence has been ac-
cumulated that suggests that soluble, not yet identified,
hIAPP oligomers might be the main mediators of
hIAPP-amyloid-associated cell toxicity [8–11]. Soluble
aggregates have been suggested to permeabilize cell
membranes via a channel- or pore-like mechanism or
simply by causing small membrane defects [9, 10, 12,
15, 61]. An important implication of these findings for
the design of inhibitors of hIAPP cytotoxicity is that—
depending on the mechanism of its action—a com-
pound that inhibits hIAPP-amyloid formation may not
necessarily inhibit cytotoxicity and vice versa [62]. The
synthetic peptide hIAPP(24–29) or GAILSST, for exam-
ple, has been reported to reduce hIAPP amyloid forma-
tion but was unable to affect its cytotoxicity, and or-
ganic compounds that inhibited hIAPP cytotoxicity or
membrane activity did not inhibit amyloid-fibril forma-
tion [15, 16, 18–20, 63].
We tested the effect of NF(N-Me)GA(N-Me)IL on
hIAPP β cell toxicity by using two different cytotoxicity
assays. First, the MTT reduction assay was applied [43,
44]. NF(N-Me)GA(N-Me)IL was found to significantly re-
duce hIAPP cytotoxicity even at a molar ratio of NF
(N-Me)GA(N-Me)IL to hIAPP of 0.1 to 1. By contrast,
no inhibitory effect was found for the control peptides
NFGAIL, AA(N-Me)GA(N-Me)VV, and the scrambled
N-methylated sequence (N-Me)IAF(N-Me)GNL. We also
studied the effect of NF(N-Me)GA(N-Me)IL on hIAPP-
mediated β cell apoptosis [7, 15, 46, 47]. Assessment
of apoptotic death is not only an additional method to
the MTT reduction for determining cell viability but also
represents a highly sensitive technique to investigate
the mechanism of cell death and/or its inhibition [46–
49]. The results were consistent with the results of the
MTT assay and showed that NF(N-Me)GA(N-Me)IL at
a 0.1 molar ratio to hIAPP significantly reduced hIAPP
apoptosis of β cells. For comparison, hIAPP(20–25) or
SNNFGA, which is the only other reported peptide in-
hibitor of hIAPP cytotoxicity, reduces hIAPP cytotoxic-
ity at a 20-fold molar excess as compared to hIAPP [20].
The results of our studies also suggested that NF(N-
Me)GA(N-Me)IL was unable to completely inhibit hIAPP
fibrillogenesis and cytotoxicity. These findings are con-
sistent with the results of the fluorescence-based
hIAPP binding assay. Thus, it appears possible that
NF(N-Me)GA(N-Me)IL might interact with monomeric or
β sheet edge strands of soluble, β sheet hIAPP oligo-
mers, most likely similarly to a NFGAIL-containing β
strand of full-length hIAPP [22]. Alignment of a strand
of the N-methylated peptide on a growing β sheet oligo-
mer would, possibly, prohibit or delay further sheet ex-
tension because of interruption of the H-bonding po-
tential of the edge hIAPP strand [22]. On the other
hand, the highly cooperative nature of the hIAPP self-
assembly and fibrillogenesis processes and the high
affinity of the Fluos-hIAPP-hIAPP interaction, whichaccording to our fluorescence binding assay, was esti-
mated to be about 13-fold-stronger than the affinity of
the Fluos-hIAPP-NF(N-Me)GA(N-Me)IL interaction, might
account for the lack of NF(N-Me)GA(N-Me)IL to com-
pletely abolish fibrillogenesis, to stop already-nucle-
ated amyloidogenesis processes, and to completely in-
hibit their cytotoxic effects [14, 41].
More detailed studies will be necessary to fully
understand the mechanism of inhibition of hIAPP fibril-
logenesis and cytotoxicity by NF(N-Me)GA(N-Me)IL.
Taken together, however, the results of our studies were
consistent with each other and suggested that NF(N-
Me)GA(N-Me)IL is able to delay and reduce the extent
of hIAPP fibrillogenesis and to reduce the cytotoxic ef-
fect of hIAPP aggregates. The inhibitory effects were
strongest when the inhibitor was applied at a 10-fold
molar excess, whereas significant effects were ob-
served even at a 10-fold-lower inhibitor concentration
as compared to hIAPP. According to our EM, ThT, and
CD studies, the observed reduction of cytotoxicity of
IAPP in the presence of NF(N-Me)GA(N-Me)IL was as-
sociated with the formation or stabilization of pre- or
nonfibrillar spherical oligomeric assemblies. These lat-
ter assemblies and/or their dissociation products ap-
pear to cause less damage to the cells than the assem-
blies of the IAPP-alone solutions and consist of either
IAPP-IAPP or IAPP-NF(N-Me)GA(N-Me)IL complexes.
The detailed biophysical characterization of these as-
semblies and their comparison with the potentially cy-
totoxic prefibrillar IAPP species reported before will al-
low for understanding IAPP β cell toxicity [8–11].
Our results also suggested that the presence of the
N-methyl rests at Gly24 and Ile26 in the hIAPP self-
recognition sequence NFGAIL is a necessary structural
requirement for the high-affinity binding of NF(N-Me)
GA(N-Me)IL to hIAPP and its inhibitory effect on hIAPP
fibrillogenesis and cell toxicity. NF(N-Me)GA(N-Me)IL is
a strongly conformationally constrained hexapeptide [22,
26, 35]. The reduced entropic barrier of NF(N-Me)GA
(N-Me)IL toward binding to hIAPP, its specific confor-
mational features, and its nonamyloidogenic character,
as compared to the nonconstrained and amyloidogenic
sequence NFGAIL, might underlie the high-affinity
binding of NF(N-Me)GA(N-Me)IL to hIAPP and its inhibi-
tory potential on both hIAPP fibrillogenesis and cyto-
toxicity [26].
Finally, fluorescently labeled NF(N-Me)GA(N-Me)IL
was found to be able to bind and stain in vivo-formed
human pancreatic-amyloid deposits [64]. This is the
first report of a partial hIAPP sequence (or an analog
thereof) that stains in vivo-formed pancreatic-amyloid
deposits. Although labeled hIAPP or several hIAPP par-
tial sequences might possibly also be able to bind or
stain pancreatic amyloid, their potential use as nonin-
vasive pancreatic-amyloid diagnostic probes would be
strongly limited because of synthetic difficulties, their
high aggregation propensities, their low solubilities,
and/or their cytotoxic effects [8, 29]. Therefore, the sig-
nificance of this latter finding might be associated with
the improved biophysical properties of NF(N-Me)GA
(N-Me)IL, including high solubility, no cytotoxicity, and,
possibly, enhanced proteolytic stability and its simpler
synthesis as compared to hIAPP and its agregation-
prone fragments [22, 26, 65]. Labeled NF(N-Me)GA(N-
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806Me)IL or its analogs could thus be candidates for po- i
ttential applications as noninvasive diagnostic probes
for type II diabetes [1, 22, 66].
Based on the above results, we conclude that NF E
(N-Me)GA(N-Me)IL is a potent inhibitor of hIAPP fibrillo-
genesis and cell death. This hexapeptide is the first re- M
Sported, designed nanomolar affinity hIAPP ligand and
bthe first N-methylated hIAPP amyloid-core-containing
ginhibitor of full-length hIAPP fibrillogenesis and cell
a
death. Therefore, the data presented here offer a clear s
proof of principle of the applicability of the amyloid- n
core-selective N-methylation strategy to the design of
inhibitors of hIAPP amyloidogenesis and cytotoxicity. P
Because amide bond N-methylation is a well-known P
strategy to increase in vivo half-life and improve the s
Rpharmacological properties of peptidic compounds,
sNF(N-Me)GA(N-Me)IL may become a lead compound
cfor the development of drugs for the treatment of type
pII diabetes [26, 65].
m
1
DSignificance
a
aType II diabetes is a progressive  cell-degenerative
pdisease that affects today about 200 million people
o
worldwide. Cell degeneration and the pathogenesis of f
this disease are strongly associated with the aggrega- V
tion of the 37-residue polypeptide hIAPP into pancre-
atic-amyloid fibrils. The hexapeptide hIAPP(22–27), or ENFGAIL, has amyloidogenic and cytotoxic properties 1
and has been suggested to be a hIAPP “amyloid b
acore,” i.e., a sequence that participates in hIAPP self-
aassociation into  sheets and fibrils. We have recently
ashown that NFGAIL can be converted into a nonamy-
loidogenic and noncytotoxic sequence via the ratio-
nal introduction of N-methyl rests at Gly24 and Ile26. A
IThe N-methylated analog NF(N-Me)GA(N-Me)IL has
ialso been found to be able to interact with NFGAIL
1and to inhibit its fibrillogenesis. Here, we show that
iNF(N-Me)GA(N-Me)IL is able to bind with nanomolar w
affinity full length hIAPP and to inhibit its fibrillogen- 2
aesis. Inhibition is characterized by a delay of the fibril-
2logenesis onset and a strong reduction of amount of
sfibrils formed. Most importantly, the N-methylated
fhexapeptide is shown to significantly reduce hIAPP-
s
aggregate-mediated  cell damage and apoptotic  1
cell death. Fluorescently labeled NF(N-Me)GA(N-Me)
IL is also shown to bind and stain in vivo-deposited
Thuman pancreatic amyloid. Studies with control hexa-
Speptides, including NFGAIL, the scrambled sequence ((N-Me)IAF(N-Me)GNL, and an N-methylated PrP se- p
4quence, suggested a high specificity of the NF(N-Me)
(GA(N-Me)IL-hIAPP interaction and the related inhibi-
mtory effects on hIAPP fibrillogenesis and cytotoxicity.
aThese studies demonstrate that two rationally intro-
cduced N-methylations of amide bonds are able to (
convert a short hIAPP amyloid-core sequence into a N
Nhigh-affinity hIAPP ligand that is also able to inhibit
thIAPP fibrillogenesis and cytotoxicity. Because NF
H(N-Me)GA(N-Me)IL is a highly soluble, nonamyloido-
lgenic, and noncytotoxic hexapeptide, these results
b
suggest that NF(N-Me)GA(N-Me)IL and/or other ratio- i
nally N-methylated hIAPP amyloid-core sequences w
fmay be promising candidates as inhibitors of, or non-nvasive amyloid diagnostic probes for, type II diabe-
es pathogenesis.
xperimental Procedures
aterials
ynthetic human hIAPP was obtained from Calbiochem-Nova-
iochem (Bad Soden, Germany), dissolved into HFIP (Aldrich,
rade 99%+) at 200–500 M, filtered over 0.2 m filter (Milllipore),
nd stored at 4°C [13, 33]. The exact concentration of hIAPP stock
olutions was determined by measuring UV absorbance at 274.5
m [67].
eptide Synthesis, Purification, and Characterization
eptides, including the fluorescein-labeled peptides, were synthe-
ized by Fmoc-solid phase synthetic (SPPS) protocols, purified by
P-HPLC, and characterized by fast atom bombardment mass
pectroscopy (FAB-MS) as recently described [22, 29]. The fluores-
ein label was introduced to the N terminus of synthetic, HPLC-
urified NF(N-Me)GA(N-Me)IL in a solution of the peptide (10 mg/
l) in 0.1 M NaHCO3 buffer with DMSO (buffer to DMSO ratio was
:1) with 5(6)-carboxyfluorescein-N-hydroxysuccinimide ester (Roche
iagnostics GmbH, Mannheim, Germany) in a 3-fold molar excess,
nd the progress of the reaction was followed by RP-HPLC. After
ccomplishment of the reaction (5 hr), the labeled peptide was
urified by RP-HPLC and characterized by MALDI. Nα-terminal-flu-
rescein-labeled hIAPP was prepared via Fmoc-based SPPS, puri-
ied by RP-HPLC, and characterized by MALDI (L.-M.Y., M.T.-N., A.
elkova, A. Kazantzis, and A.K., unpublished data).
lectron Microscopy
0–50 l aliquots of solutions or suspensions were applied on car-
on-coated grids, stained with uranyl acetate as described [13],
nd examined with a Zeiss EM 109 electron microscope operated
t 80 kV or with a Philips EM 400 T electron microscope operated
t 60 kV.
ggregation Assays with CD and EM
ncubations of hIAPP alone (5 M) or mixtures of hIAPP (5 M) with
nhibitor or control peptides were performed in the CD cuvette in
0 mM sodium phosphate buffer (pH 7.4) (CD assay buffer) contain-
ng 1% HFIP (final concentration) as described [8, 13]. CD spectra
ere collected at various time points with a Jasco J-720 or an AVIV
02SF spectropolarimeter. CD spectra were collected between 195
nd 250 nm at 0.2 nm intervals, a response time of 8 s, and at
5°C. CD spectra (mean residue ellipticities [θ]) are presented after
ubtracting the spectra of buffer alone. At indicated time points,
ibril formation was examined by EM (see above) of aliquots of the
olutions or pellets of suspensions after centrifugation (10 min at
2,000 × g) and resuspension into 10 l of bidestilled water.
hioflavin T Binding Assay
olutions containing hIAPP (6.25 M) in 10 mM Tris buffer (pH 7.4)
assay buffer), in the absence or presence of inhibitor or control
eptide were incubated for 14 days. At the indicated time points,
0 l aliquots were diluted into 160 l of a thioflavin T (ThT) solution
5 M ThT in 0.1 M glycine/NaOH [pH 8.5]) and ThT binding was
easured as described [45]. An increase in fluorescence emission
t 486 nm (measured in triplicate) after excitation at 450 nm indi-
ated increased hIAPP amyloid formation. For the 1:0.1 hIAPP/NF
N-Me)GA(N-Me)IL incubations, assay buffer solution containing
F(N-Me)GA(N-Me)IL was added to hIAPP. For the 1:10 hIAPP/
F(N-Me)GA(N-Me)IL incubations, reproducible results were ob-
ained when NF(N-Me)GA(N-Me)IL was first mixed with hIAPP in
FIP and, after evaporation of the HFIP, the remaining film-like pel-
et was then diluted into the assay buffer. Incubations in assay
uffer with 1%–2% HFIP were performed to study the effect of the
nhibitor on a prenucleated system [14]. In preliminary experiments,
e found that the fluorescence emission of ThT bound to hIAPP
ibrils was proportional to amyloid fibril concentration.
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807Analysis of the Composition of Precipitated Aggregates
After peptide precipitation in a CD experiment, the suspension (800
l) was centrifuged (12,000 × g; 10 min), and the pellet redissolved
in 100 l DMSO and injected onto a Nucleosil 100 C-18 semipre-
parative column (Grom, Herrenberg, Germany) (100 Å pore size,
7 m paricle size, 8 × 250 mm). Supernatants were also analyzed
by RP-HPLC. Eluents and flow rates were as previously described
[29], and the peptides were identified by their retention times.
Assessment of Cell Viability with the MTT Reduction Assay
The rat insulinoma cell line RIN 5fm was obtained by T.E. Rucinsky
from the Washington University Tissue Culture Support Center, and
cells were cultured as described [29]. Cells were plated in 96-well
plates at a density of 5 × 105 cells/ml (100 l/well) [29]. After incu-
bation for 24 hr (37°C, humidified atmosphere with 5% CO2), serial
dilutions of a seedless hIAPP solution (5 M, in 10 mM sodium
phosphate buffer [pH 7.4] [assay buffer]) or solutions containing a
mixture of seedless hIAPP (5 M) with NF(N-Me)GA(N-Me)IL,
NFGAIL, PrP(117-122), or (N-Me)IAF(N-Me)GNL (at 50 M or 500
nM) were applied to the cells. After incubation for 20 hr, cell viability
was assessed by measuring the cellular reduction of MTT as de-
scribed [29, 43]. In all studies, a dose-response curve of hIAPP
alone was obtained in parallel to the mixture curves to control for
differences in hIAPP cytotoxicity because of variations in its aggre-
gation states. The incubations that were made to study the effect
of NFGAIL on hIAPP cytotoxicity (Figure 5B) contained 1% HFIP
because of the low solubility of NFGAIL. We obtained more repro-
ducible results in the hIAPP/peptide incubations at a 1:10 molar
ratio when the peptides were first mixed with hIAPP in HFIP and,
after evaporation of the HFIP, the remaining pellet was then diluted
into the assay buffer.
Assessment of Apoptosis
Cells (see above) were platted in 12-well plates at a density of 5 ×
105 cells/ml (750 l/well). After incubation for 24 hr (37°C, humidi-
fied atmosphere with 5% CO2), hIAPP (5 M, in 10 mM sodium
phosphate buffer [pH 7.4]) or a solution containing a mixture of
hIAPP (5 M) with NF(N-Me)GA(N-Me)IL (500 nM) or vehicle alone
were applied to the cells at a peptide final concentration of 500 nM
hIAPP alone or 500 nM hIAPP and 50 nM NF(N-Me)GA(N-Me)IL.
After incubation for 20 hr (37°C, humidified atmosphere with 5%
CO2), cells were detached from the wells by treatment with a tryp-
sin/EDTA solution and counted, and apoptosis was assessed by
the Cell Death Detection ELISA kit (Roche Diagnostics, Mann-
heim, Germany).
Binding of NF(N-Me)GA(N-Me)IL to Soluble,
Fluorescein-Labeled hIAPP
Fluorescence measurements were performed on a Spex Fluorolog
2 fluorescence spectrophotometer with a 1 cm path-length cuvette.
Excitation was at 492 nm, and fluorescence emission spectra be-
tween 500 and 600 nm were recorded. The exact concentration of
Fluos-hIAPP (freshly made stock solution in HFIP) was determined
by UV spectroscopy. All fluorescence measurements were per-
formed in 10 mM sodium phosphate buffer (pH 7.4) containing 1%
HFIP at room temperature within the first 2–5 min after solution
preparation. Both hIAPP and NF(N-Me)GA(N-Me)IL or the control
peptides were added to the aqueous buffer solution from suitable
stock solutions in HFIP. In Figure 6B, the maximum fluorescence
intensities of various mixtures of Fluos-hIAPP and NF(N-Me)GA
(N-Me)IL at 522 nm (after subtraction of the fluorescence of Fluos-
hIAPP) were plotted versus the logarithm of free NF(N-Me)GA
(N-Me)IL concentration. Because the concentration of Fluos-hIAPP
is more than 100-fold lower than the apparent Kd of the complex,
the concentration of added NF(N-Me)GA(N-Me)IL was assumed to
be approximately the same as the concentration of free NF(N-Me)
GA(N-Me)IL [58]. Sigmoidal curve fitting and determination of the
apparent Kd were performed with GraphPad Prism software using
the following equation: F = F0 + [(Fsat − F0) / (1 + 10(LogKd-L).HillSlope)]
in which F is the observed fluorescence intensity, F0 is the fluores-
cence of Fluos-hIAPP alone, Fsat is the fluorescence intensity at
saturation, L is the logarithm of the concentration of NF(N-Me)
GA(N-Me)IL, and K is the apparent dissociation constant [60, 68].dStudying the Binding of Fluorescein-Labeled Peptides
to Deposits of Human Pancreatic Amyloid
and Canine Renal AA Amyloid
Human pancreatic tissue with islet amyloid obtained postmortem
and canine renal tissue with reactive (AA) amyloidosis were stored
frozen at −20°C. Frozen sections (10 m) were mounted on glass
slides and fixed in ice-cold acetone for 10 min and rinsed five times
in 10 mM sodium phosphate buffer with 0.15 sodium cloride (PBS)
(pH 7.4). Sections were incubated with fluorescently labeled pep-
tides NF(N-Me)GA(N-Me)IL, NFGAIL, or hIAPP(1–13) (10 M in PBS).
Incubation took place in a humidity chamber at room temperature
for 12 hr. After incubation, the sections were rinsed in PBS and
mounted with Vectashield mounting medium (Vector laboratories,
Burlingame, CA). Consecutive sections were stained for amyloid
with Congo red [50, 64]. Fluorescent staining was studied on a Ni-
kon eclipse E800 microscope equipped with an excitation filter at
450 nm for detection of fluorescein fluorescence and an excitation
filter at 546 nm for detection of Congo red fluorescence [50, 64].
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